Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) concerning potential violations of the federal securities laws.
On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026. GeneDx then reported Q1 2026 adjusted EPS of -$0.28 -- versus consensus expectations of -$0.01 -- representing an adjusted net loss of $8.2 million in the same quarter management had projected would be profitable. The stock fell approximately 41% to 49% after Q1 2026 results, as adjusted EPS of $0.28 significantly missed consensus -$0.01 consensus, widening the gap between the numbers investors were given and the results that followed.
If you suffered a loss on your GeneDx Holdings Corp. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





